Anoro Ellipta Powder
Product Images NDC 0173-0869

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Anoro Ellipta (NDC 0173-0869). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Umeclidinium Bromide Chemical Structure (Anoro Ellipta Spl Graphic 01)

FDA Label Image

Vilanterol Trifenatate Chemical Structure (Anoro Ellipta Spl Graphic 02)

FDA Label Image

Figure 1. Impact Of Intrinsic Factors On The Pharmacokinetics (pk) Of Umeclidinium (umec) And Vilanterol (vi) (Anoro Ellipta Spl Graphic 03)

FDA Label Image

Figure 2. Impact Of Extrinsic Factors On The Pharmacokinetics (pk) Of Umeclidinium (umec) And Vilanterol (vi) (Anoro Ellipta Spl Graphic 04)

FDA Label Image

Figure 3. Least Squares (ls) Mean Change From Baseline In Postdose Serial Fev1 (ml) On Days 1 And 7, Day 1 (Anoro Ellipta Spl Graphic 05)

FDA Label Image

Figure 3. Least Squares (ls) Mean Change From Baseline In Postdose Serial Fev1 (ml) On Days 1 And 7, Day 7 (Anoro Ellipta Spl Graphic 06)

FDA Label Image

Figure 4. Least Squares (ls) Mean Change From Baseline In Postdose Serial Fev1 (0-24 H) (ml) On Days 1 And 28, Day 1 (Anoro Ellipta Spl Graphic 07)

Figure 4. Least Squares (ls) Mean Change From Baseline In Postdose Serial Fev1 (0-24 H) (ml) On Days 1 And 28, Day 1 (Anoro Ellipta Spl Graphic 07)
Not Available.*
FDA Label Image

Figure 4. Least Squares (ls) Mean Change From Baseline In Postdose Serial Fev1 (0-24 H) (ml) On Days 1 And 28, Day 28 (Anoro Ellipta Spl Graphic 08)

FDA Label Image

Figure 5. Least Squares (ls) Mean Change From Baseline In Fev1 (ml) Over Time (0-24 H) On Days 1 And 168 (trial 1 Subset Population), Day 1 (Anoro Ellipta Spl Graphic 09)

FDA Label Image

Figure 5. Least Squares (ls) Mean Change From Baseline In Fev1 (ml) Over Time (0-24 H) On Days 1 And 168 (trial 1 Subset Population), Day 168 (Anoro Ellipta Spl Graphic 10)

FDA Label Image

Inhaler Parts Figure (Anoro Ellipta Spl Graphic 11)

Inhaler Parts Figure (Anoro Ellipta Spl Graphic 11)
The text is describing two separate items, a "Tray Lid" and a "Carton". It is not possible to determine the specific details or features of these items based on this text alone.*
FDA Label Image

Figure A (Anoro Ellipta Spl Graphic 12)

FDA Label Image

Figure B (Anoro Ellipta Spl Graphic 13)

FDA Label Image

Figure C (Anoro Ellipta Spl Graphic 14)

FDA Label Image

Figure D (Anoro Ellipta Spl Graphic 15)

FDA Label Image

Figure E (Anoro Ellipta Spl Graphic 16)

FDA Label Image

Figure F (Anoro Ellipta Spl Graphic 17)

FDA Label Image

Figure G (Anoro Ellipta Spl Graphic 18)

Figure G (Anoro Ellipta Spl Graphic 18)
This text is a safety instruction advising not to block an air vent with fingers.*
FDA Label Image

Figure H (Anoro Ellipta Spl Graphic 19)

FDA Label Image

Figure I (Anoro Ellipta Spl Graphic 20)

FDA Label Image

Figure J (Anoro Ellipta Spl Graphic 21)

FDA Label Image

Figure K (Anoro Ellipta Spl Graphic 22)

FDA Label Image

Anoro Ellipta 30 Dose Carton (Anoro Ellipta Spl Graphic 23)

Anoro Ellipta 30 Dose Carton (Anoro Ellipta Spl Graphic 23)
ANORO Ellipta is a prescription medication that contains a combination of umeclidinium and vilanterol. It comes as an inhalation powder for oral inhalation only. Each strip contains blisters of umeclidinium or vilanterol with magnesium stearate and lactose monohydrate. The product comes with 30 doses and a total of 60 blisters. The NDC code for ANORO Ellipta is 0173-0869-10. It is important to note that it is Rx only, meaning it requires a prescription from a healthcare provider.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.